MIR1180: A Potential Drug Target and Biomarker (G100302256)
MIR1180: A Potential Drug Target and Biomarker
MIR1180, a protein encoded by the MIR1180 gene, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for drug development, and various studies have investigated its potential utility as a therapeutic agent.
The MIR1180 gene is located on chromosome 6p21.2 and encodes a protein of 21 kDa, which is expressed in various tissues and cells of the body. The protein has a unique structure, with a catalytic domain, a transmembrane region, and a cytoplasmic tail. The catalytic domain is composed of a Rossmann-fold, a common structural motif that is known to participate in protein-protein interactions and catalytic activity. The transmembrane region is composed of multiple domains, including a putative transmembranespanner (TMSP) and a protein-coding region (PCR). The cytoplasmic tail is composed of multiple domains, including a nucleotide-binding oligomerization domain (NBO), a helix-turn-helix (HTH) domain, and a C-terminal hypervariable region (HVR).
MIR1180 has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and metabolism. It has been shown to be involved in the regulation of cell adhesion, cell cycle progression, and apoptosis. In addition, MIR1180 has been shown to be involved in the regulation of inflammation, pain perception, and neurodegenerative diseases.
As a potential drug target, MIR1180 has been investigated for its ability to modulate cellular processes that are associated with various diseases. For example, MIR1180 has been shown to play a role in the regulation of cell adhesion and cytoskeletal organization, which are associated with various diseases, including cancer. In addition, MIR1180 has been shown to play a role in the regulation of the cell cycle and apoptosis, which are associated with neurodegenerative diseases.
MIR1180 has also been shown to be involved in the regulation of inflammation and pain perception, which are associated with various diseases, including chronic pain and neurodegenerative diseases. In addition, MIR1180 has been shown to play a role in the regulation of cellular signaling pathways, including T cell development and activation, which are associated with autoimmune diseases.
As a potential biomarker, MIR1180 has been shown to be involved in the regulation of cellular processes that are associated with various diseases. For example, MIR1180 has been shown to play a role in the regulation of cell adhesion and cytoskeletal organization, which are associated with cancer. In addition, MIR1180 has been shown to play a role in the regulation of the cell cycle and apoptosis, which are associated with neurodegenerative diseases.
In addition to its potential drug target and biomarker properties, MIR1180 has also been shown to have potential therapeutic applications in various diseases. For example, MIR1180 has been shown to be involved in the regulation of cancer cell migration and invasion, which are associated with the development of cancer. In addition, MIR1180 has been shown to play a role in the regulation of pain perception and neurodegenerative diseases, which are associated with chronic pain and neurodegenerative diseases.
In conclusion, MIR1180 is a protein that has been identified as a potential drug target and biomarker in various diseases. Its unique structure and function have made it an attractive target for drug development, and various studies have shown its potential utility as a therapeutic agent in
Protein Name: MicroRNA 1180
The "MIR1180 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1180 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1
